Table 3.
Prevalence of HPV biomarkers in oral exfoliated cells and serum among healthy individuals in the MOUTH cohort in the screening (at-risk) population, and in the higher risk of MACS/WIHS participants enrolled because they had HPV biomarkers detected in a previous study
| Prevalence | ||
|---|---|---|
| Biomarkers | At-Risk (MOUTH Screening) | High-risk (MACS/WIHS CCS) |
| Oral rinse HPV | N = 294 | N = 133 |
| HPV16 | ||
| SPF10 DEIA | 2.0% | 10.5% |
| Cobas DNA | 2.4% | 15.0% |
| Any oncogenic typea | ||
| SPF10 DEIA | 4.4% | 39.9% |
| Cobas DNA | 4.8% | 45.9% |
| Aptima RNAb | 0.3% | 6.0% |
| Any HPV type: SPF10 DEIA | 12.6% | 53.4% |
| HPV serum antibodiesc | N = 172 | N = 126 |
| HPV16 | ||
| E1 antibody | 2.3% | 1.6% |
| E2 antibody | 0.6% | 0.8% |
| E6 antibody | 2.3% | 2.4% |
| E7 antibody | 5.2% | 8.7% |
| E6 and E7 antibodies | 0.0% | 0.8% |
| E6 and/or E7 antibodies | 7.6% | 10.3% |
| E1, E2, E6, E7 (≥3 of these 4) | 0.0% | 0.8% |
| E1, E2, E6, and/or E7 (any) | 9.9% | 11.1% |
| Any oncogenic typea | ||
| E6 antibody | 6.4% | 11.1% |
| E7 antibody | 7.0% | 15.9% |
| E6 and E7 antibodies | 0.6% | 4.0% |
| E6 and/or E7 antibodies | 12.8% | 23.0% |
| Cotesting of HPV16 | ||
| Cotesting by oral rinse DNA and serum antibodies | ||
| Both: HPV16 DEIA and E6 antibody | 0.0% | 1.6% |
| Either: HPV16 DEIA and/or E6 antibody | 4.1% | 11.9% |
| Any of: HPV16 DEIA, Cobas, and/or E6 antibody | 4.7% | 16.7% |
| Any of: HPV16 DEIA, Cobas, E6 and/or E7 antibodies | 9.4% | 24.6% |
Oral rinse and serum included these 8 oncogenic HPV types: 16, 18, 31, 33, 35, 45, 52, 58; In addition, oral rinse (but not serum) test also included in oncogenic definition these 6 types: 39, 51, 56, 59, 66, (and type 68 for Cobas and Aptima but not DEIA).
Among MOUTH participants, Aptima testing was only performed among those who were HPV positive by DEIA - other samples assumed to be negative by Aptima for calculation of prevalence (based on dual testing of 151 HOTSPOT HPV-OPC cases and controls by both DEIA and Aptima, showing that 150 (99.3%) of 151 DEIA negative samples were negative by Aptima.
Serum antibody results were only available in a subset of participants at the time this paper was written as the next batch of test results were not yet completed.